Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 12/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449493 | 1.00 | GSK3B (0.49) | GSK3BPIM1PIM2HPGDRXRA | |
| SCHEMBL5492867 | 0.89 | GSK3B (0.49) | GSK3BPIM1PIM2HPGDRXRA | |
| SCHEMBL5492870 | 0.89 | GSK3B (0.49) | GSK3BPIM1PIM2HPGDRXRA | |
| SCHEMBL14492755 | 0.89 | GSK3B (0.49) | GSK3BPIM1PIM2HPGDRXRA | |
| SCHEMBL6028171 | 0.84 | GSK3B (0.44) | GSK3BPIM1PIM2HPGDRXRA | |
| SCHEMBL6028169 | 0.84 | GSK3B (0.44) | GSK3BPIM1PIM2HPGDRXRA | |
| SCHEMBL14492774 | 0.81 | PIM1 (0.52) | GSK3BPIM1PIM2HPGDPIM3 | |
| SCHEMBL5488100 | 0.81 | PIM1 (0.52) | GSK3BPIM1PIM2HPGDPIM3 | |
| SCHEMBL5488097 | 0.81 | PIM1 (0.52) | GSK3BPIM1PIM2HPGDPIM3 | |
| SCHEMBL7461584 | 0.81 | GSK3B (0.49) | GSK3BPIM1PIM2HPGDRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | claimed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | GSK3B 2758/4885PIM1 708/4885PIM2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.